tiprankstipranks
Advertisement
Advertisement

REGN Stock Latest News

Citizens biotechnology analyst holds analyst/industry conference call
The FlyCitizens biotechnology analyst holds analyst/industry conference call
20h ago
AZ
GSK
Telix Pharmaceuticals up 11% to $11.70 after collaboration with Regeneron
PremiumThe Fly
Telix Pharmaceuticals up 11% to $11.70 after collaboration with Regeneron
2d ago
REGN
Telix Pharmaceuticals, Regeneron announce radiopharma collaboration
PremiumThe Fly
Telix Pharmaceuticals, Regeneron announce radiopharma collaboration
2d ago
REGN
Regeneron, Sanofi announce European Commission approval for Dupixent indication
PremiumThe Fly
Regeneron, Sanofi announce European Commission approval for Dupixent indication
2d ago
SNY
REGN
Regeneron price target raised to $796 from $769 at Morgan Stanley
PremiumThe Fly
Regeneron price target raised to $796 from $769 at Morgan Stanley
5d ago
REGN
Regeneron price target lowered to $921 from $925 at Bernstein
PremiumThe FlyRegeneron price target lowered to $921 from $925 at Bernstein
7d ago
REGN
Regeneron price target raised to $779 from $765 at RBC Capital
Premium
The Fly
Regeneron price target raised to $779 from $765 at RBC Capital
8d ago
REGN
Regeneron to invest up to $200M in TriNetX as part of strategic collaboration
Premium
The Fly
Regeneron to invest up to $200M in TriNetX as part of strategic collaboration
13d ago
REGN
Regeneron announces FDA approval of extension of dosing intervals for EYLEA HD
PremiumThe Fly
Regeneron announces FDA approval of extension of dosing intervals for EYLEA HD
13d ago
REGN
Regeneron’s High-Dose Aflibercept Trial in China Nears a Key Inflection Point for Eye-Care Growth
PremiumCompany Announcements
Regeneron’s High-Dose Aflibercept Trial in China Nears a Key Inflection Point for Eye-Care Growth
15d ago
REGN
Regeneron price target lowered to $801 from $818 at Truist
PremiumThe Fly
Regeneron price target lowered to $801 from $818 at Truist
15d ago
REGN
Regeneron assumed with an Overweight at Piper Sandler
PremiumThe Fly
Regeneron assumed with an Overweight at Piper Sandler
15d ago
REGN
Regeneron, Sanofi get approval for Dupixent to treat bullous pemphigoid in Japan
PremiumThe FlyRegeneron, Sanofi get approval for Dupixent to treat bullous pemphigoid in Japan
22d ago
SNY
REGN
Get Ready for a $5.7 Trillion ‘Triple-Witching’ Event on Friday
Premium
Market News
Get Ready for a $5.7 Trillion ‘Triple-Witching’ Event on Friday
27d ago
DIA
PDD
Regeneron price target raised to $825 from $800 at Wells Fargo
Premium
The Fly
Regeneron price target raised to $825 from $800 at Wells Fargo
27d ago
REGN
Vertex Pharmaceuticals price target raised to $550 from $515 at Wells Fargo
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $550 from $515 at Wells Fargo
27d ago
AMGN
REGN
Amgen price target raised to $390 from $375 at Wells Fargo
PremiumThe Fly
Amgen price target raised to $390 from $375 at Wells Fargo
27d ago
AMGN
REGN
Regeneron and Sanofi Extend Phase 3 Itepekimab Program in Chronic Sinus Disease
PremiumCompany Announcements
Regeneron and Sanofi Extend Phase 3 Itepekimab Program in Chronic Sinus Disease
30d ago
SNY
REGN
Dupilumab Study Tracks Mental Health Benefits in Atopic Dermatitis Patients Across Gulf Countries
PremiumCompany Announcements
Dupilumab Study Tracks Mental Health Benefits in Atopic Dermatitis Patients Across Gulf Countries
1M ago
SNY
REGN
Regeneron says Hansoh shares topline data from Phase 3 trial of olatorepatide
PremiumThe FlyRegeneron says Hansoh shares topline data from Phase 3 trial of olatorepatide
1M ago
REGN
Regeneron initiated with an Overweight at Barclays
Premium
The Fly
Regeneron initiated with an Overweight at Barclays
1M ago
REGN
Regeneron and Sanofi Complete Key Dupilumab Pregnancy Safety Study With Fresh Data Update
Premium
Company Announcements
Regeneron and Sanofi Complete Key Dupilumab Pregnancy Safety Study With Fresh Data Update
1M ago
REGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >